Cambridge, Massachusetts, September 15, 2026
QurCan Therapeutics has entered into a strategic research and collaboration agreement with Eli Lilly and Company to advance the discovery and development of nucleic acid therapies for diseases of the central and peripheral nervous systems. The collaboration brings together QurCan’s expertise in RNA and nucleic acid drug discovery with Lilly’s global capabilities in neuroscience research, pharmaceutical development and clinical translation. The agreement represents a significant development in the effort to create new therapeutic approaches for neurological disorders, where delivering medicines to the appropriate tissues and cells remains one of the industry’s most complex challenges. By combining complementary technologies and research capabilities, the companies aim to identify and advance novel nucleic acid-based therapeutic programs targeting important diseases of the central nervous system (CNS) and peripheral nervous system (PNS).
QurCan and Lilly Establish Strategic Collaboration
The collaboration is designed to leverage QurCan Therapeutics’ proprietary research capabilities together with Lilly’s extensive expertise in drug development. QurCan is focused on discovering and developing nucleic acid medicines designed to modulate disease-associated biological pathways, while Lilly brings substantial experience in neuroscience, translational research and advancing therapeutic candidates through pharmaceutical development. Nucleic acid medicines include therapeutic approaches such as RNA-based therapies, antisense oligonucleotides and other forms of genetic medicine designed to influence the expression or function of disease-associated genes. These technologies can potentially address biological targets that are difficult to reach using traditional small-molecule drugs or antibodies. The strategic research agreement reflects the increasing interest among major pharmaceutical companies in partnering with specialized biotechnology companies to access innovative drug-discovery platforms. For QurCan, the collaboration with Lilly provides an opportunity to combine its technology and scientific expertise with the resources and development capabilities of a global pharmaceutical company.
Advancing CNS and Peripheral Nervous System Research
Diseases affecting the central and peripheral nervous systems represent a major area of unmet medical need. Neurological disorders can involve complex biological mechanisms and may affect multiple cell types and tissues, making the development of effective therapies particularly challenging. One of the potential advantages of nucleic acid therapeutics is their ability to selectively influence specific molecular pathways. Researchers can design nucleic acid medicines to target particular RNA sequences or gene-expression processes, potentially enabling highly specific therapeutic interventions. However, successful development also requires overcoming challenges associated with drug delivery, tissue penetration, stability, cellular uptake and safety. These challenges are especially important in CNS diseases because the blood-brain barrier can restrict the movement of many therapeutic molecules from the bloodstream into the brain. Developing technologies that can efficiently deliver nucleic acid medicines to relevant neural tissues could therefore have significant implications for future neurological drug development. The QurCan-Lilly collaboration is positioned within this broader scientific effort to develop next-generation nucleic acid medicines capable of addressing diseases that have historically been difficult to treat.
Advertisement
Partnership Strengthens Nucleic Acid Drug Discovery
Strategic partnerships between biotechnology companies and large pharmaceutical organizations are increasingly important in accelerating innovative therapeutic development. Smaller biotechnology companies often bring specialized technologies and novel scientific approaches, while global pharmaceutical companies can provide extensive expertise in development, regulatory strategy, manufacturing and commercialization. For Lilly, the agreement expands its access to emerging nucleic acid technologies that could complement its existing neuroscience research. Lilly has maintained a significant focus on neurological diseases and is investing in approaches designed to address disease mechanisms at increasingly precise biological levels. For QurCan, the collaboration represents an opportunity to advance its research through access to Lilly’s broader scientific and development capabilities. The companies will work together to identify potential therapeutic opportunities in CNS and PNS diseases, with the goal of translating promising discoveries into drug-development programs. The agreement also highlights the growing convergence of genetic medicine and neuroscience.
As researchers gain a better understanding of the molecular mechanisms underlying neurological diseases, nucleic acid technologies may provide new ways to selectively modify disease pathways rather than relying only on traditional pharmacological approaches. The collaboration does not mean that a new medicine has been approved or that a specific therapy has demonstrated clinical efficacy. Instead, it represents an early-stage research and development partnership aimed at discovering and advancing potential therapeutic candidates.For cGxP.wire readers, the QurCan Therapeutics and Lilly agreement is an important development in biopharmaceutical innovation and neuroscience drug discovery. The partnership demonstrates the pharmaceutical industry’s increasing interest in nucleic acid technologies and their potential application to difficult-to-treat neurological diseases. Continued research will determine whether the collaboration can generate viable therapeutic candidates and ultimately translate advances in nucleic acid science into new treatment options for patients with central and peripheral nervous system disorders.
Source: QurCan Therapeutics, Eli Lilly press release
